These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Sullivan MA; Vosburg SK; Comer SD Psychopharmacology (Berl); 2006 Nov; 189(1):37-46. PubMed ID: 16972105 [TBL] [Abstract][Full Text] [Related]
3. Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial. Sullivan MA; Rothenberg JL; Vosburg SK; Church SH; Feldman SJ; Epstein EM; Kleber HD; Nunes EV Am J Addict; 2006; 15(2):150-9. PubMed ID: 16595353 [TBL] [Abstract][Full Text] [Related]
4. Long-acting depot formulations of naltrexone for heroin dependence: a review. Krupitsky EM; Blokhina EA Curr Opin Psychiatry; 2010 May; 23(3):210-4. PubMed ID: 20224403 [TBL] [Abstract][Full Text] [Related]
5. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Carroll KM; Ball SA; Nich C; O'Connor PG; Eagan DA; Frankforter TL; Triffleman EG; Shi J; Rounsaville BJ Arch Gen Psychiatry; 2001 Aug; 58(8):755-61. PubMed ID: 11483141 [TBL] [Abstract][Full Text] [Related]
6. Contingency management for treatment of substance abuse. Stitzer M; Petry N Annu Rev Clin Psychol; 2006; 2():411-34. PubMed ID: 17716077 [TBL] [Abstract][Full Text] [Related]
7. Experiences with an outpatient relapse program (community reinforcement approach) combined with naltrexone in the treatment of opioid-dependence: effect on addictive behaviors and the predictive value of psychiatric comorbidity. Roozen HG; Kerkhof AJ; van den Brink W Eur Addict Res; 2003 Apr; 9(2):53-8. PubMed ID: 12644730 [TBL] [Abstract][Full Text] [Related]
8. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Comer SD; Sullivan MA; Yu E; Rothenberg JL; Kleber HD; Kampman K; Dackis C; O'Brien CP Arch Gen Psychiatry; 2006 Feb; 63(2):210-8. PubMed ID: 16461865 [TBL] [Abstract][Full Text] [Related]
9. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Comer SD; Collins ED; Kleber HD; Nuwayser ES; Kerrigan JH; Fischman MW Psychopharmacology (Berl); 2002 Feb; 159(4):351-60. PubMed ID: 11823887 [TBL] [Abstract][Full Text] [Related]
10. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Preston KL; Umbricht A; Epstein DH Arch Gen Psychiatry; 2000 Apr; 57(4):395-404. PubMed ID: 10768702 [TBL] [Abstract][Full Text] [Related]
11. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Nunes EV; Rothenberg JL; Sullivan MA; Carpenter KM; Kleber HD Am J Drug Alcohol Abuse; 2006; 32(4):503-17. PubMed ID: 17127538 [TBL] [Abstract][Full Text] [Related]
12. Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone. Sullivan MA; Bisaga A; Glass A; Mishlen K; Pavlicova M; Carpenter KM; Mariani JJ; Levin FR; Nunes EV Drug Alcohol Depend; 2015 Feb; 147():122-9. PubMed ID: 25555621 [TBL] [Abstract][Full Text] [Related]
13. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Wahlgren V; Tsoy-Podosenin M; Bushara N; Burakov A; Masalov D; Romanova T; Tyurina A; Palatkin V; Slavina T; Pecoraro A; Woody GE Arch Gen Psychiatry; 2012 Sep; 69(9):973-81. PubMed ID: 22945623 [TBL] [Abstract][Full Text] [Related]
14. Risk-taking propensity as a predictor of induction onto naltrexone treatment for opioid dependence. Aklin WM; Severtson SG; Umbricht A; Fingerhood M; Bigelow GE; Lejuez CW; Silverman K J Clin Psychiatry; 2012 Aug; 73(8):e1056-61. PubMed ID: 22967782 [TBL] [Abstract][Full Text] [Related]
16. Effects of incentives for naltrexone adherence on opiate abstinence in heroin-dependent adults. Jarvis BP; Holtyn AF; DeFulio A; Dunn KE; Everly JJ; Leoutsakos JS; Umbricht A; Fingerhood M; Bigelow GE; Silverman K Addiction; 2017 May; 112(5):830-837. PubMed ID: 27936293 [TBL] [Abstract][Full Text] [Related]
17. Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder. Carroll KM; Nich C; Frankforter TL; Yip SW; Kiluk BD; DeVito EE; Sofuoglu M Drug Alcohol Depend; 2018 Nov; 192():264-270. PubMed ID: 30300800 [TBL] [Abstract][Full Text] [Related]